iSpecimen Presents New Research to Optimize Biobanking at International Society for Biological and Environmental Repositories 2022 Annual Meeting

Rhea-AI Summary

iSpecimen (NASDAQ: ISPC) presented three key discussions at the ISBER Annual Meeting in Atlanta, focusing on the evolution of biobanking through advanced technology.

Chief Operating Officer Jill Mullan outlined how precision medicine drives the need for 'just-in-time' biospecimen collections, leveraging five years of data from the iSpecimen Marketplace. Key insights highlighted the transition from traditional inventory methods to a dynamic, online inventory system.

Additional talks included the journey of iSpecimen from ideation to IPO and an interactive demo of the enhanced Marketplace platform.

Positive

• Presentation of insights on 'just-in-time' biobanking aligns with the growth in precision medicine.
• Utilization of five years of search data from the iSpecimen Marketplace enhances market positioning.
• Innovative online platform aims to streamline specimen procurement and inventory management.

Negative

• None.

Company Gave Three Presentations, Including Oral Discussion on How New Technology Can Support the “Just-in-Time” Approach to Biobanking

LEXINGTON, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ: ISPC) (“iSpecimen” or the “Company”), a global online marketplace that connects scientists in need of biospecimens for medical research with healthcare organizations that can provide them, announced today that the Company gave three presentations at this year’s International Society for Biological and Environmental Repositories (ISBER) Annual Meeting in Atlanta, Ga.

Jill Mullan, iSpecimen’s Chief Operating Officer, gave an oral presentation on an accepted abstract titled, “Biospecimen Matchmaking: The Data-Driven Journey from Internal Spreadsheets to Online Inventories to Just-in-Time Biobanking.” The presentation focused on how, after two decades, biobanks are now at a crossroads, as precision medicine requires more customized biospecimen collections with complex patient inclusion criteria that often cannot be fulfilled through existing inventories.

iSpecimen analyzed researcher request data, including five years of specimen search data from its proprietary iSpecimen Marketplace platform, to provide insights into how precision medicine is driving the need for "just-in-time" biospecimen collections. iSpecimen used this data to propose requirements for a next-generation biobanking solution that incorporates an online platform using biobanking inventory data, along with in-depth healthcare datasets, to:        

• Connect biorepositories to a global network of researchers who need specimens and data
• Enable efficient specimen and patient inventory matchmaking across a federated provider network
• Automate inventory-based and just-in-time biobanking workflows from inquiry to invoice
• Provide data-driven insights using AI to help align inventory management and market demand

Key findings and conclusions from iSpecimen’s analysis included:

• Many researchers anticipate that the biospecimens they source to advance their work will come from both banked inventories and custom collections in 2022.
• The best biobank is an active, empty one, rather than a repository with specimens collected from years ago that are never used.
• To get there, biorepository managers need to consider solutions that include advanced matchmaking and easy search functionality to make existing inventories more accessible, along with just-in-time biobanking approaches to accommodate prospective collections as needed.
• When it comes to sourcing biospecimens, researchers’ preferred approach is using an online platform / marketplace.
• A key to creating an effective bio procurement solution is the coupling of in-depth healthcare datasets and researcher demand data with AI and analysis tools to bring efficiencies to the biospecimen procurement process, all while helping to drive smarter biobanking inventory strategies.
  

“Traditionally, biobanking involved an inventory-based approach whereby internal researchers leveraged biospecimen samples stored and collected over time, with simple patient inclusion criteria and limited datasets,” said Ms. Mullan. “However, today, that approach only provides part of the solution because of the advent and rise of precision medicine. In a world where custom research requests come in constantly and new therapies are developed for patients more frequently, what may have been collected and stored years ago may not be relevant for researchers now.”

Ms. Mullan continued, “With the just-in-time approach, the entire world can be a researcher’s biobank, thanks to big data and technologies like AI. Rather than taking and storing point-in-time samples, biobanks should be based off access to patient populations, enabling them to obtain samples in real-time. This allows the process to become more fluid and helpful for researchers. The bottom line is that biobanks need to become more than just repositories for specimens; they are conduits for just-in-time specimen collections from their patient population inventory. iSpecimen’s Marketplace is the solution, as it offers intuitive multi-site search functionality for both banked and prospective specimens and accessible patient details, all in one place for researchers.”

In addition to Ms. Mullan’s oral presentation, Dr. Christopher Ianelli, M.D., Ph.D., iSpecimen’s Founder and CEO, gave a presentation during the plenary session titled, “From Ideation to IPO: One Company’s Journey to Commercialize a Biospecimen Solution.” The third presentation came from Dr. Ianelli and Emily Hubbard, iSpecimen’s Vice President, Site Development, titled, “An Innovation Solution for Just-in-Time Biobanking,” which included an interactive demo of iSpecimen’s new, enhanced Marketplace platform.

About iSpecimen
iSpecimen (NASDAQ: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.

For further information, please contact:

Investor Contact
KCSA Strategic Communications
Allison Soss
iSpecimen@kcsa.com

Media Contacts
KCSA Strategic Communications
Raquel Cona / Shana Marino
iSpecimen@kcsa.com

FAQ

What were the key topics discussed by iSpecimen at the ISBER Annual Meeting?

iSpecimen discussed the evolution of biobanking and the 'just-in-time' approach using advanced technology.

How does iSpecimen's Marketplace improve biospecimen procurement?

The Marketplace connects researchers with biorepositories, automating workflows and providing data-driven insights.

What is the significance of 'just-in-time' biobanking according to iSpecimen?

'Just-in-time' biobanking allows researchers to obtain relevant specimens in real-time, enhancing research efficiency.

What data did iSpecimen analyze to support their presentations?

iSpecimen analyzed five years of specimen search data from its proprietary Marketplace platform.

Who presented at the ISBER Annual Meeting on behalf of iSpecimen?

Jill Mullan (COO) and Dr. Christopher Ianelli (CEO) presented key discussions on biobanking innovations.